Alkermes plc

ALKS ·Healthcare, Drug Manufacturers - General, Ireland
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $-157.9M $-208.4M $-227.2M $-30.1M $20.6M $-113.7M $-45.5M $-39.6M
Depreciation & Amortization $98.5M $94.3M $85.6M $98.1M $73.8M $47.9M $8.7M $25.0M
Depreciation $36.5M $33.3M $27.9M $39.9M $31.9M $22.5M $8.7M $25.0M
Amortization $62.1M $61.0M $57.7M $58.2M $41.9M $25.4M — —
Stock-Based Compensation $83.9M $94.4M $97.3M $59.6M $34.7M $28.8M $19.8M $13.9M
Net Cash from Operating Activities $19.2M $-63.8M $-40.4M $11.1M $147.5M $-2.5M $-5.9M $-12.2M
Investing Activities
Capital Expenditures $51.3M $43.7M $52.9M $33.7M $22.2M $17.0M $9.4M $15.8M
Business Acquisitions — — — — — $494.8M — —
Net Cash from Investing Activities $-18.4M $127.2M $-43.5M — — $-417.2M $5.6M $28.0M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — $2.7M
Net Cash from Financing Activities $4.1M $-58.2M $40.9M — — $464.8M $-40.7M $-23.3M
Net Change in Cash $4.9M $5.3M $-43.0M $56.5M — $45.2M $-40.9M $-7.6M
Free Cash Flow $-32.1M $-107.5M $-93.2M $-22.5M $125.3M $-19.5M $-15.3M $-28.0M
← Newer Page 2 of 2 Older →